See the DrugPatentWatch profile for Inveltys
Inveltys is a brand name for a medication containing the active ingredient lanadelumab [1]. It is used to treat hereditary angioedema (HAE) [1, 2].
How does Inveltys work to treat HAE?
Inveltys works by targeting plasma kallikrein [1, 3]. This enzyme plays a key role in the pathway that leads to the swelling attacks characteristic of HAE [3]. By inhibiting plasma kallikrein, Inveltys helps to reduce the frequency of these attacks [1, 3].
What is hereditary angioedema (HAE)?
Hereditary angioedema is a rare genetic disorder that causes recurrent episodes of swelling in various parts of the body, including the limbs, abdomen, face, and airway [2, 4]. These swelling attacks can be painful and, in cases involving the airway, can be life-threatening [2, 4]. HAE is caused by a deficiency or dysfunction of the C1 inhibitor protein [4].
When does the patent for Inveltys expire?
Information regarding the specific patent expiry dates for Inveltys (lanadelumab) is available through patent tracking resources [5]. DrugPatentWatch.com provides detailed patent information that can help determine when exclusivity for this drug may end [5].
What are the alternatives to Inveltys for HAE treatment?
Treatment options for HAE can vary. Other therapies may include medications that target different pathways involved in HAE or medications that replace or supplement the deficient C1 inhibitor [4]. A healthcare professional can determine the most suitable treatment plan based on an individual's specific condition and needs.